130 related articles for article (PubMed ID: 38670802)
1.
Zhang W; Oh JH; Zhang W; Aldrich CC; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2024 Apr; ():. PubMed ID: 38670802
[TBL] [Abstract][Full Text] [Related]
2. Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors.
Zhang W; Oh JH; Zhang W; Rathi S; Larson JD; Wechsler-Reya RJ; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2023 Dec; 387(3):315-327. PubMed ID: 37827699
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.
Wang EC; Min Y; Palm RC; Fiordalisi JJ; Wagner KT; Hyder N; Cox AD; Caster JM; Tian X; Wang AZ
Biomaterials; 2015 May; 51():208-215. PubMed ID: 25771011
[TBL] [Abstract][Full Text] [Related]
5. Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity.
Oh JH; Power EA; Zhang W; Daniels DJ; Elmquist WF
J Pharmacol Exp Ther; 2022 Oct; 383(1):44-55. PubMed ID: 36279392
[TBL] [Abstract][Full Text] [Related]
6. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
[TBL] [Abstract][Full Text] [Related]
7.
Zhang W; Oh JH; Zhang W; Aldrich CC; Sirianni RW; Elmquist WF
J Pharmacol Exp Ther; 2024 Feb; 389(1):96-105. PubMed ID: 38409112
[TBL] [Abstract][Full Text] [Related]
8. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios.
Kalvass JC; Maurer TS; Pollack GM
Drug Metab Dispos; 2007 Apr; 35(4):660-6. PubMed ID: 17237155
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
Wang C; Eessalu TE; Barth VN; Mitch CH; Wagner FF; Hong Y; Neelamegam R; Schroeder FA; Holson EB; Haggarty SJ; Hooker JM
Am J Nucl Med Mol Imaging; 2013; 4(1):29-38. PubMed ID: 24380043
[TBL] [Abstract][Full Text] [Related]
10. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
11. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
[TBL] [Abstract][Full Text] [Related]
13. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
[TBL] [Abstract][Full Text] [Related]
14. Unbound Brain-to-Plasma Partition Coefficient, K
Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
[TBL] [Abstract][Full Text] [Related]
15. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
16. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L
Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963
[TBL] [Abstract][Full Text] [Related]
18. Muscle to Brain Partitioning as Measure of Transporter-Mediated Efflux at the Rat Blood-Brain Barrier and Its Implementation into Compound Optimization in Drug Discovery.
Cui Y; Lotz R; Rapp H; Klinder K; Himstedt A; Sauer A
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31718023
[TBL] [Abstract][Full Text] [Related]
19. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]